Alivus Life
Alivus Life Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
3 of 4 strong
Not discussed on this call: fundraise.
The short version
Alivus Life Sciences expects revenue growth of 10% to 12% in FY '27, with stronger growth skewed towards the second half of the year. Revenue Growth: Alivus is guiding for 10% to 12% revenue growth in FY '27, with growth skewed towards the second half of the year.
From Alivus Life's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Alivus Life Sciences expects revenue growth of 10% to 12% in FY '27, with stronger growth skewed towards the second half of the year.
- Non-GPL business is driving strong growth, with a 26.5% year-on-year increase in Q1 FY '27, supported by a robust product pipeline and recent launches.
- CDMO business is anticipated to accelerate in H2 FY '27 and beyond as new projects commercialize, contributing to faster growth than the overall business.
- The company is working on 7 active CDMO projects and anticipates closing 2 new CDMO contracts in early H2 FY '27.
- Pipeline of 28-29 new high-potent API products being commercialized gradually, with significant launches expected from FY '28 onward.
- Volume growth in non-GPL business is about 21-22%, with price declines around 1-2%.
- Capacity expansions at Dahej and Ankleshwar as well as Solapur (operational by early Q3 FY '27) will support double-digit growth in FY '27 and FY '28.
Profitability & Margins
See what Alivus Life said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capex for Q1 FY '27 was INR85 crores; expected capex for FY '27 is approximately INR540 crores.
- Priority capex focus remains on completion of expansions at Dahej (160KL increase) and Ankleshwar (110KL increase), both on track.
- Solapur Phase 1 and 1.1 nearing completion, to be operational by Q3 FY '27, with inspections planned within a year post-operation for regulatory approvals.
- Solapur expansion (Phase 3) has been delayed by about a year to avoid under-absorption and is planned as a greenfield project.
- New R&D center construction at Taloja has begun and is progressing on schedule.
- Investment focus on new API launches and improving manufacturing capabilities, especially for regulated markets.
- Strategic investments targeted at synergistic acquisitions focusing on pipeline expansion rather than merely facility acquisition.
- Overall, capex and strategic investments are calibrated to support double-digit growth while maintaining operational efficiency.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Alivus Life said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Alivus Life Sciences is actively engaged in about 7 ongoing CDMO projects.
- Revenue currently comes from 5 existing projects.
- There are new inquiries beyond these 7 projects, indicating a steady flow of potential business.
- The CDMO segment is expected to accelerate growth in H2 FY '27 and continue expanding in FY '28 with new projects kicking in.
- The company is confident of maintaining steady demand and growth from its existing pipeline and new launches.
- The robust product pipeline includes 29 active high-potent API products with a total addressable market of $82 billion.
- The Solapur facility is being readied to increase capacity and contribute to order fulfillment once regulatory approvals are completed.
- Overall, Alivus expects orderbook growth driven by new launches, lifecycle management, and specialty CDMO projects.
Alivus Life — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹689 Cr, net profit ₹163 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Alivus Life Sciences Ltd's management said in earlier quarters
- Q2 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q1 FY26 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Novartis India Ltd (Q1 FY27)
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
- IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Frequently Asked Questions
What were Alivus Life Q1 FY27 results?
Alivus Life Sciences expects revenue growth of 10% to 12% in FY '27, with stronger growth skewed towards the second half of the year. Revenue Growth: Alivus is guiding for 10% to 12% revenue growth in FY '27, with growth skewed towards the second half of the year.
What is Alivus Life share price analysis?
Alivus Life currently shows a below-average growth signal. The stock trades at a P/E of 26.7 with a market cap of ₹16,585 Cr. Investors should review the full earnings analysis for detailed insights.
Is Alivus Life planning capital expenditure?
Capex for Q1 FY '27 was INR85 crores; expected capex for FY '27 is approximately INR540 crores.
Keep Alivus Life on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.